Albemarle vs Eastman Chemical
ALB and EMN side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALB and EMN compare
Albemarle is the larger company, worth 1.4 times as much as Eastman Chemical ($10.7B against $7.6B).
On earnings, Eastman Chemical is cheaper: it trades at 12.2× trailing earnings, against 337× for Albemarle.
Albemarle grew revenue faster over the last twelve months (18.3% versus 0.27% for Eastman Chemical).
Eastman Chemical keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with 3.8% at Albemarle.
Both pay dividends: Albemarle yields 1.8% and Eastman Chemical 5.1%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALB | EMN |
|---|---|---|
| Size and price | ||
| Market cap | $10.7B | $7.6B |
| Share price | $91.00 | $66.53 |
| Change, 1 year | −7.0% | 8.9% |
| Change, 5 years | −66.6% | −40.5% |
| Beta (5Y) | 1.68 | 1.10 |
| Employees | 7,800 | 13K |
| StockData Score | ||
| Total score | 16 | 16 |
| Valuation score | 4 | 5 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 4 | 6 (better) |
| Valuation | ||
| P/E | 337× | 12.2× (better) |
| P/S | 1.8× | 0.8× (better) |
| P/B | 1.0× (better) | 1.2× |
| EV/EBITDA | 12.6× | – |
| P/FCF | 8.0× (better) | 16.2× |
| FCF yield | 12.5% (better) | 6.2% |
| Fair value | $117.07 | $87.53 |
| Margin of safety | 22.3% | 24.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 18.3% (better) | 0.27% |
| Revenue growth, 5Y average | 10.4% (better) | 0.65% |
| Net income growth (TTM) | – | −13.3% |
| EPS growth (TTM) | – | −12.3% |
| EPS growth, 5Y average | – | 3.2% |
| Profitability | ||
| Gross margin | 23.8% (better) | 20.6% |
| Operating margin | 4.3% | – |
| Net margin | 3.8% | 6.9% (better) |
| FCF margin | 22.7% (better) | 5.2% |
| Return on equity | 2.2% | 10.4% (better) |
| Return on invested capital | 1.1% | – |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.83 |
| Net debt / EBITDA | 0.27 | – |
| Current ratio | 2.09 (better) | 1.57 |
| Altman Z-score | 2.24 (better) | 2.15 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.8% | 5.1% (better) |
| Payout ratio | 85.0% | 61.1% |
| Years of dividend growth | 16 | 16 |
| Dividend growth, 5Y average | 1.0% | 4.5% (better) |
| Shareholder yield | 1.8% | 5.1% (better) |
| Ownership | ||
| Held by institutions | 98.3% | 94.1% |
| Held by insiders | 0.35% | 0.83% |
| Insider net buying, 12 months | −$7.4M | −$366K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.0% | 5.9% |
Go deeper
- ALB stock overview
- ALB income statement
- ALB valuation and score
- EMN stock overview
- EMN income statement
- EMN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.